Amneal Pharmaceuticals Financial Statements
NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amneal Pharmaceuticals revenue and earnings
In fiscal 2025, Amneal Pharmaceuticals generated $3.02 billion in revenue, up 8.0% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $72.1 million, for a net margin of 2.4% versus a median of -3.5% in the prior 5 years. Gross margin was 36.9% (up from 36.5%) and operating margin 13.1%.
Diluted earnings per share came in at $0.22. Over the last 5 fiscal years, AMRX's revenue has grown at a 8.7% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Amneal Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.02B | 2.79B | 2.39B | 2.21B | 2.09B | 1.99B | 1.63B | 1.66B | 1.03B | 1.02B |
| Revenue growth (YoY) | +8.05% | +16.73% | +8.20% | +5.67% | +5.08% | +22.51% | -2.20% | +60.88% | +1.52% | — |
| Cost of Revenue | 1.91B | 1.77B | 1.57B | 1.43B | 1.32B | 1.33B | 1.15B | 938.77M | 507.48M | 420.77M |
| Gross Profit | 1.11B | 1.02B | 820.57M | 784.71M | 768.97M | 628.39M | 353.00M | 716.40M | 526.18M | 597.46M |
| Operating Expenses | 719.21M | 771.11M | 616.19M | 879.64M | 616.26M | 537.24M | 601.68M | 736.08M | 281.07M | 312.57M |
| Research & Development | 186.18M | 190.71M | 163.95M | 195.69M | 201.85M | 179.93M | 188.05M | 194.19M | 171.42M | 179.02M |
| Selling, General & Admin | 526.83M | 476.44M | 429.68M | 399.70M | 365.50M | 326.73M | 289.60M | 227.85M | 109.05M | 118.76M |
| Operating Income | 394.10M | 249.33M | 204.37M | -94.93M | 152.72M | 91.16M | -248.68M | -19.67M | 245.10M | 284.88M |
| Other Income (Expense) | -254.89M | -304.34M | -244.64M | -153.20M | -121.35M | -126.94M | 28.44M | -183.05M | -73.78M | -70.06M |
| Pretax Income | 139.21M | -55.01M | -40.27M | -248.13M | 31.37M | -35.78M | -220.24M | -202.72M | 171.32M | 214.82M |
| Income Tax | 11.28M | 18.86M | 8.45M | 6.66M | 11.20M | -104.36M | 383.33M | -1.42M | 2.00M | 5.39M |
| Net Income | 72.06M | -116.89M | -83.99M | -270.58M | 13.16M | 67.79M | -603.57M | -19.74M | 0 | 0 |
| Net Income growth (YoY) | — | — | — | -2155.64% | -80.58% | — | — | — | — | — |
| EPS (Basic) | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 | 0.62 | -2.74 | -0.16 | — | — |
| EPS (Diluted) | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 | 0.61 | -2.74 | -0.16 | — | — |
| Shares Outstanding (Basic) | 313.37M | 308.98M | 176.14M | 150.94M | 148.92M | 147.44M | 132.11M | 127.25M | — | — |
| Shares Outstanding (Diluted) | 324.81M | 308.98M | 176.14M | 150.94M | 151.82M | 148.91M | 132.11M | 127.25M | — | — |
| EBITDA | 451.40M | 311.93M | 270.57M | -26.83M | 213.42M | 151.57M | -185.40M | 44.74M | 287.06M | 314.19M |
| Gross Margin | 36.88% | 36.52% | 34.28% | 35.47% | 36.73% | 31.54% | 21.70% | 43.08% | 50.90% | 58.68% |
| Operating Margin | 13.05% | 8.92% | 8.54% | -4.29% | 7.29% | 4.57% | -15.29% | -118.00% | 23.71% | 27.98% |
| Net Margin | 2.39% | -4.18% | -3.51% | -12.23% | 63.00% | 3.40% | -37.11% | -119.00% | 0.00% | 0.00% |
This table shows 10 annual periods of Amneal Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AMRX's reporting calendar. What is a income statement?